Vanessa Malier (L) and Rémi Droller, managing partners at Kurma Partners
March 8, 2022 10:38 AM ESTUpdated 03:29 PM
Financing

Kur­ma scores $175M in first clos­ing of biotech/healthtech fund — the VC's largest yet

Paul Schloesser

Associate Editor

French VC Kur­ma has been in­vest­ing in­to sev­er­al com­pa­nies re­cent­ly, such as AR­M­GO Phar­ma and Emer­gence Ther­a­peu­tics. With its new biotech and healthtech-fo­cused fund, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times